By the time a sponsor sends you an RFP, they have already decided you are one of a few CROs worth asking. The selection that mattered happened weeks earlier, and you were not part of it.
We run the directory sponsors use to build those lists, so here is what the process actually looks like from the other side.
The RFP is the end, not the beginning
Most CROs treat the RFP as the start of the sales process. It is closer to the end. Before it arrives, a sponsor has defined the trial, worked out what capability they need, asked a few colleagues who they used, searched, and browsed a category directory to see who exists. Out of that comes a list of three, four, maybe five CROs.
Everything after that is a competition among the companies who made the list. Everything before it decided who did.
What sponsors are actually filtering on
When a sponsor scans a directory of CROs, they are not reading carefully. They are filtering fast, on a handful of things.
- Therapeutic fit. Do you run trials like theirs? An oncology sponsor looking at a CRO with no visible oncology experience moves on in seconds, regardless of how capable you are.
- Phase and trial type. Early-phase dose escalation and a global registrational study demand completely different things. Sponsors know this, and they filter for it.
- Scale. A small biotech is trying to work out whether they will be a priority client or a rounding error. A large sponsor is trying to work out whether you can handle the footprint.
- Geography. Where can you actually run sites?
- Evidence you are real. A name with no description reads as a company that either does not care or does not exist anymore.
Notice how much of that is answerable from a profile, and how little of it requires a conversation.
The mistake most CROs make
The mistake is presenting as a full-service CRO that does everything for everyone. It feels safe. It is actually the fastest way to be forgotten.
Sponsors are not looking for a CRO. They are looking for their CRO: the one that has run this kind of trial, in this therapeutic area, at this phase, in these countries. A generic profile answers none of those questions, so the sponsor cannot tell whether you fit, and a sponsor who cannot tell whether you fit does not put you on a shortlist. They move to the next entry, which is more specific.
Specificity feels like it narrows your market. In practice it is the only thing that gets you into any market at all.
The enrollment question behind every decision
There is one thing sponsors care about more than anything else on your capabilities list, and most CROs bury it: can you actually enroll the trial?
Trials fail on recruitment far more often than they fail on execution. A sponsor evaluating CROs is, underneath everything, trying to answer whether you can find their patients. If your profile speaks to relevant therapeutic experience, site relationships, and demonstrated enrollment in comparable studies, you are addressing the fear that actually keeps them up at night. If it lists services, you are answering a question they did not ask.
Where the search happens
Sponsors find CROs through referrals, through search, and through category directories, which is where a sponsor goes when they want to see who exists rather than who they already know.
That last channel is the one CROs neglect and the one that most rewards attention, because a sponsor browsing a CRO directory is not researching idly. They have a trial. They need a partner. They are building a list right now.
And sometimes they skip the browsing entirely and write to us directly, asking who they should be talking to. When that happens, we can only put forward companies whose capabilities we actually have on file. Recently a top-five global pharmaceutical company did exactly that, looking for a partner for a program. A name in a database is not something anyone can recommend. A real profile is.
Be the company they find
Sponsors are building CRO shortlists this week. Some of them will write to us asking who to call. The only question is whether your company is part of that answer.
Get a featured listing and dedicated landing page, $5,000/year
Or start with a featured profile, $3,000/year
Both carry a 90-day guarantee: if your listing does not generate measurable referral traffic, we extend it by a quarter at no cost. Browse the CRO directory to see exactly where your company would sit, and read how biotech buyers actually choose vendors for the wider picture.
Frequently asked questions
How do sponsors choose a CRO?
Sponsors build a shortlist before sending an RFP. They define the trial, work out what capability they need, ask colleagues, search, and browse category directories, narrowing to three to five CROs. They filter fast on therapeutic fit, phase and trial type, scale, geography, and whether the CRO appears credible and current. Only then do they make contact.
What do sponsors look for in a CRO profile?
Therapeutic and trial-type fit above all, since a sponsor with an oncology trial will skip a CRO showing no oncology experience. They also assess phase experience, scale, geographic reach, and, underneath everything, whether the CRO can actually enroll the trial, since recruitment is where trials most often fail.
How can a small CRO compete for business?
By being specific rather than generic. Sponsors are not looking for a CRO, they are looking for their CRO: one that has run this kind of trial, in this therapeutic area, at this phase, in these countries. A generic full-service profile answers none of those questions, so sponsors cannot assess fit and move on. Specificity is what gets you shortlisted.
